Business Wire

AlertEnterprise Reveals New Guardian Platform Integration With Nedap AEOS Access Control System

Share

AlertEnterprise, Inc., the leading cyber-physical security convergence software company, today announced a new integration with Nedap AEOS access control platform. This cyber-physical integration connects Nedap AEOS with AlertEnterprise Guardian AI-powered physical identity access management (PIAM) cloud platform for automated, secure and compliant workplace access.

Say goodbye to clunky, outdated manual approaches to access control. With this integration, businesses of all sizes can finally bridge the gap between IT security controls and physical security measures, all while leveraging AI to streamline the process of managing user identities and building access.

As Yogesh Ailawadi, AlertEnterprise SVP of Product Management and Solution Engineering puts it, "In the new reality of the hybrid workplace, organizations are wasting valuable resources and increasing risk with outdated manual approaches to access control. By interfacing AlertEnterprise Guardian with Nedap AEOS, companies can close security gaps and digitally transform workplace access within their existing PACS infrastructure investments."

Thanks to intelligent data collection and normalization from both Nedap AEOS systems and other identity sources such as HR databases and IT directory services, Guardian’s AI platform helps organizations to proactively enforce policies in real-time, automating building access based on job role, training and certification, and more without the need to manually update each individual record in the system.

“I’m very pleased to have AlertEnterprise joining our Technology Partner Programme. They really bring added value by making people and authorization management simple. Powerful features like self-service portals and automated authorization approval workflows for supervisors and managers, is something our customers often find challenging. Now the answer is simple, AlertEnterprise.” Wesley Keegstra, Integration Manager at Nedap Security Management

The integration provides a unified cyber-physical identity access management solution for businesses of all sizes across industries by closing existing gaps between IT security controls and physical security measures—while providing more efficient, compliant, and automated ways of managing user identities and building access.

To learn more about Guardian, visit: https://alertenterprise.com/industry-solutions/workplace-access/

AlertEnterprise

At AlertEnterprise, cyber-physical identity and trust are at the center of everything we do. Our mission is to bring people, processes, data and technology together in a unique way to help organizations protect what matters most. We call it security convergence. And we develop game-changing security convergence solutions that deliver identity governance, access management, security intelligence and compliance validation across enterprise IT, HR, cyber and physical security environments.

About Nedap N.V.

Nedap is a Dutch multinational technology company, responsible for the development of powerful solutions in physical security. Their access control system, AEOS, is based entirely on open standards and designed to adapt to your ever-changing needs. It’s the ultimate foundation for any application of physical access control – from businesses to government offices, hospitals, airports, schools, industrial sites and public venues. AEOS goes beyond opening doors, making people feel safe and protecting your valuable assets. It lets you decide how to react and respond to specific situations. www.nedapsecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Willem Ryan – Senior Vice President of Marketing and Communications
Email: media@alertenterprise.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

REGiMMUNE Limited Licenses the Rights to Develop and Commercialize RGI-2001 To San Fu Biotech in Major Asian Countries1.4.2023 18:18:00 CEST | Press release

REGiMMUNE Limited (REGiMMUNE), a biotech company focused on creating innovative immunotherapies for immune disorders and cancer, and San Fu Biotech (SFB), a subsidiary of San Fu Chemical Co., Ltd. (4755.TW) have entered a licensing agreement to develop and commercialize RGI-2001 for the prophylaxis of acute Graft-versus-host disease (aGvHD) in major Asian countries. RGI-2001, with the novel mechanism to improve existing treatments, is a potentially first-in-class small molecule drug candidate targeted for preventing aGvHD, a life-threatening complication resulting from allogeneic hematopoietic stem cell transplantation (HSCT). GvHD is a systemic disorder that occurs when the graft's immune cells recognize the host as foreign and attack the recipient’s body cells or organs, and leads to skin rash, liver problems, abdominal pain or cramps, diarrhea, and increased risk for infections. Patients undergoing allogeneic HSCT have a high-risk of developing aGVHD associated with significant morb

AriBio Co., Ltd. to Present Biomarker Data for AR1001 from the Mild to Moderate Alzheimer’s Disease Phase 2 Study at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD™ 2023)31.3.2023 18:00:00 CEST | Press release

AriBio Co., Ltd. announced that David Greeley MD, Chief Medical Officer at AriBio, will present biomarker data from the completed phase 2 study in patients with mild to moderate Alzheimer’s disease who were treated with 10mg and 30mg of AR1001. AR1001 is a potent PDE5 inhibitor with preliminary efficacy in cognition, and preclinical effects on neuron apoptosis inhibition, promotion of neurogenesis, increase in neuroplasticity, and stimulation of autophagy to remove toxic proteins. The phase 2 study was a double-blind, randomized, placebo-controlled, multi-center trial to evaluate the safety and preliminary efficacy of AR1001 over 26 and 52 weeks of treatment in patients with mild to moderate Alzheimer’s disease. The trial enrolled 210 patients at 21 research centers in the United States. Plasma collected from patients at baseline, week 26 and week 52 was analyzed by Quantarix using the Simoa HD-X analyzer. Meaningful, statistically significant changes were found over 52 weeks of treatm

KANEKA: “Development of Polymer Synthesis Technology by Microorganisms using CO2 as Direct Raw Material” selected as a NEDO Green Innovation Fund Project”31.3.2023 16:09:00 CEST | Press release

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO). This press release features multimedia. View the full release here: https://www.busine

Allianz Appoints Leadership for Allianz Commercial Key Markets31.3.2023 15:11:00 CEST | Press release

As part of the implementation of its ‘Integrated Commercial’ strategy to better serve the full Commercial segment, Allianz Group today announced the leadership for four of its largest Property and Casualty Commercial insurance markets: Australia, France, Germany and the United Kingdom. In each country, the appointed single Commercial lead will represent the integrated Allianz Commercial business and bring to the market Allianz’s full set of solutions for specialty clients, large corporates, and mid-sized companies, simplifying and enhancing the experience of clients and distribution partners. “The appointment of the regional leaders in our core Allianz Commercial markets is an important, concrete step toward realizing our new integrated model, which brings together our Mid Corporate and Large Corporate insurance business for the benefit of our clients and distribution partners,” said Chris Townsend, Member of the Allianz SE Board of Management. Townsend added, “As one face to the marke

Huawei Releases 2022 Annual Report: Steady Operations, Sustainable Survival and Development31.3.2023 11:59:00 CEST | Press release

Huawei released its 2022 Annual Report today. The company reports steady operations throughout 2022, having generated CNY642.3 billion in revenue and CNY35.6 billion in net profits. Huawei continues to strengthen investment in R&D, with an annual expenditure of CNY161.5 billion in 2022, representing 25.1% of the company's annual revenue and bringing its total R&D expenditure over the past 10 years to more than CNY977.3 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005166/en/ (Photo: Huawei) "In 2022, a challenging external environment and non-market factors continued to take a toll on Huawei's operations", said Eric Xu, Huawei's Rotating Chairman, at the company's annual report press conference. "In the midst of this storm, we kept racing ahead, doing everything in our power to maintain business continuity and serve our customers. We also went to great lengths to grow the harvest – generating a steady stream

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom